Humacyte vs ProKidney
HUMA and PROK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HUMA and PROK compare
ProKidney is the larger company, worth 2.1 times as much as Humacyte ($342M against $164M).
ProKidney grew revenue faster over the last twelve months (55.2% versus 52.5% for Humacyte).
Humacyte keeps more of each dollar of sales as profit, with a net margin of −3955% compared with −10288% at ProKidney.
ProKidney scores higher on the StockData Score (5 against 2 for Humacyte), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HUMA | PROK |
|---|---|---|
| Size and price | ||
| Market cap | $164M | $342M |
| Share price | $0.592 | $1.13 |
| Change, 1 year | −56.2% | −58.1% |
| Change, 5 years | −94.6% | −88.6% |
| Beta (5Y) | 2.06 | 1.32 |
| Employees | 184 | 231 |
| StockData Score | ||
| Total score | 2 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 68.6× (better) | 418× |
| P/B | 9.1× | – |
| FCF yield | −53.9% | −46.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 52.5% | 55.2% (better) |
| Profitability | ||
| Gross margin | −475% | – |
| Operating margin | −4603% (better) | −21665% |
| Net margin | −3955% (better) | −10288% |
| FCF margin | −3697% (better) | −19527% |
| Return on equity | −1424% | – |
| Financial health | ||
| Interest coverage | −11.0× (better) | −9327.2× |
| Current ratio | 3.34 | 8.36 (better) |
| Altman Z-score | −10.29 | −1.12 (better) |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | −7.1% |
| Shareholder yield | 0.00% (better) | −7.1% |
| Ownership | ||
| Held by institutions | 26.4% | 16.1% |
| Held by insiders | 8.0% | 62.9% |
| Insider net buying, 12 months | $7.4K (better) | −$1.1M |
| Short interest, % of float | 11.0% | 21.7% |
Go deeper
- HUMA stock overview
- HUMA income statement
- HUMA valuation and score
- PROK stock overview
- PROK income statement
- PROK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.